<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="235842">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006101</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068110</org_study_id>
    <secondary_id>UCIRVINE-97-18</secondary_id>
    <secondary_id>UCIRVINE-U01-CA-81886-01</secondary_id>
    <secondary_id>NCI-P00-0164</secondary_id>
    <secondary_id>NCI-2009-00890</secondary_id>
    <nct_id>NCT00006101</nct_id>
  </id_info>
  <brief_title>Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer</brief_title>
  <official_title>Randomized Placebo-Controlled, Double-Blind Phase IIb Chemoprevention Trial of Difluoromethylornithine in Brothers and First Cousin Males of Familial Prostate Cancer Probands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
      development of cancer. The use of eflornithine may be an effective way to prevent the
      development of prostate cancer.

      PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in
      preventing prostate cancer in patients who are at high risk of developing the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the levels of polyamines (putrescine, spermidine, and spermine) and
           progression-related genes in the prostate tissue of patients at high genetic risk for
           prostate cancer treated with eflornithine (DFMO) vs placebo.

        -  Determine the side effects of DFMO and compare them with the biological effect on the
           prostate gland in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
      stratified according to age (35 to 60 vs 61 to 70) and presence of localized cancer (yes vs
      no).

      All patients receive oral placebo daily for 4 weeks. Patients who are compliant and take the
      placebo 5-7 days each week are randomized to one of two arms.

        -  Arm I: Patients receive oral placebo daily.

        -  Arm II: Patients receive high-dose oral eflornithine (DFMO) daily. Treatment continues
           for 1 year in the absence of unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 100 patients (50 per arm) will be accrued for this study
      within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Eflornithine (DFMO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg/d for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eflornithine</intervention_name>
    <arm_group_label>Eflornithine (DFMO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Unaffected brother or first-degree cousin of a young (under age 70) prostate cancer
             proband with a family history (two or more first-degree relatives) of prostate cancer

          -  No prior non-localized prostate cancer or previously diagnosed premalignant prostate
             disease

        PATIENT CHARACTERISTICS:

        Age:

          -  35 to 70

        Performance status:

          -  SWOG 0-1 OR

          -  Karnofsky 70-100%

        Life expectancy:

          -  At least 5 years

        Hematopoietic:

          -  Hematocrit at least 35%

          -  WBC at least 4,000/mm^3 with normal differential

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL

          -  SGOT or SGPT less than 2 times normal

        Renal:

          -  Creatinine less than 1.5 mg/dL

          -  Less than 1+ protein, 0-3 casts, and 0-5 WBCs and RBCs in urine

        Gastrointestinal:

          -  No medically mandated special diet that would preclude compliance with study
             participation

          -  No documented or symptomatic gastric or duodenal ulcer disease within the past year

        Other:

          -  No severe metabolic disorders or other life-threatening acute or chronic disease

          -  No other invasive cancer within the past 5 years except nonmelanoma skin cancer

          -  No predisposition to difficulties with wound healing or repair

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  At least 3 months since prior finasteride

        Radiotherapy:

          -  No prior radiotherapy to pelvic area

          -  No concurrent x-rays

        Surgery:

          -  Not specified

        Other:

          -  At least 3 months since prior chemoprevention agents

          -  No aspirin or aspirin-containing products within 10 days prior to each study biopsy

          -  No concurrent anticoagulants
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne R. Simoneau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.</citation>
    <PMID>18268112</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 23, 2016</lastchanged_date>
  <firstreceived_date>August 3, 2000</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Chao Family Comprehensive Cancer Center</investigator_full_name>
    <investigator_title>Cancer Center</investigator_title>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
